WOODBURY, N.Y.--(BUSINESS WIRE)--BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research q

24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and favorable safety profile signals potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Investigator-initiated study of LYMPHIR in combination with pembrolizumab to be presented during immunotherapy session, highlighting potential role of LYMPHIR beyond CTCL CRANFORD, N.J., May 26, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biop

– Design of Confirmatory Study in Barth Syndrome to Be Presented – – Phase 3 NuPOWER Results Support Development of Elamipretide in POLG1 Subgroup – NEEDHAM, Mass., May 26, 2026 /PRNewswire/ -- Stealth BioTherapeutics (the "Company" or "Stealth"), a commercial-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced its planned presentations at the International Meeting on Mitocho

Brain organoid assay evaluates amyloid-driven pathology and neuronal function Expands suite of capabilities to model human pathogenesis and functional recovery for neurodegenerative diseases NEW ORLEANS, May 26, 2026 /PRNewswire/ -- 28bio today announced the launch of the CNS-3D Induced Alzheimer's Model, a brain organoid assay enabling researchers to evaluate whether therapeutic candidates can reduce or prevent disease progression in patients. Genetically engineered animal models and convention

SAN DIEGO, May 26, 2026 /PRNewswire/ -- Crystalys Therapeutics Inc. ('Crystalys' or 'the Company'), a clinical-stage biopharmaceutical company addressing the significant unmet medical needs of people living with gout, today announced that the first patients have been dosed in its new randomized, double-blind, placebo-controlled, multicenter Phase 2 AMETHYST study (NCT07535034) evaluating the efficacy of dotinurad in participants with gout who are intolerant to xanthine oxidase inhibitors (XOIs)

SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences: William Blair 46th Annual Growth Stock Conference Date: June 2, 2026L

ALISO VIEJO, Calif.--(BUSINESS WIRE)--ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser Syst

Watkins-based Kazmira Therapeutics launches a first-of-its-kind telehealth platform for prescription cannabis. DENVER, May 26, 2026 /PRNewswire/ -- Kazmira Therapeutics, the company behind pioneering initiatives such as Kazmira Pharmacy and Cannabidiol API, today launched Cope Now, a novel telehealth platform to deliver a regulated clinical pathway for cannabidiol (CBD) care. The launch comes shortly after Kazmira's announcement of its prescription-only CBD pharmacy, the nation's first 503A phar

Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients Identified Biomarkers May Predict Patient Response, Enable Targeted Patient Selection and Allow for Precision Medicine AUSTIN, Texas, May 26, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today annou

SK bioscience collaborates with Colombia's government-led US$260 million vaccine localization initiative through technology transfer and local manufacturing cooperation with state-owned pharmaceutical company VECOL This alliance enables SK bioscience to enter Latin America by manufacturing SKYVaricella, with potential expansion into a broader vaccine portfolio. SK–VECOL partnership establishes strategic foothold for broader LATAM expansion INCHEON, South Korea, May 26, 2026 /PRNewswire/ -- SK